Manager TitleAgeSince
Chief Executive Officer - 2026-03-31
Chief Tech/Sci/R&D Officer - 2009-07-16
Director of Finance/CFO 60 2022-06-30
Director TitleAgeSince
Director/Board Member 78 2004-08-31
Chairman 68 2021-12-08
Director/Board Member 58 2020-07-08
Change 5-day change 1-year change 3-year change Capi.($)
+0.58%+5.32%-30.89%-1.45% 90.72B
+1.63%+2.17%-15.83%-19.83% 33.86B
+1.27%+2.56%+7.18%-23.90% 14.3B
+0.83%+1.15% - - 10.31B
-0.28%+13.61%-19.55%+600.20% 2.18B
+1.88%+0.18%-39.27%-66.35% 1.48B
-1.58%+16.02%+18.60%+4.48% 902M
+0.31%+0.20%-34.26%-28.74% 875M
+14.93%+17.92%+72.54%-12.19% 850M
Average +2.16%+4.56%-5.18%+56.53% 17.28B
Weighted average by Cap. +0.94%+3.27%-22.65%+0.23%
Logo TearLab Corp
TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc., develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care. Its product, the TearLab Osmolarity System, enables the measurement of tear osmolarity in the doctor's office. The TearLab Osmolarity System consists of approximately three components: the TearLab disposable, the TearLab Pen, and the TearLab Reader. The TearLab disposable is a single-use microfluidic microchip. The TearLab Pen is a hand-held device that interfaces with the TearLab disposable. The TearLab Reader is a small desktop unit that allows for the docking of the TearLab Pen.
Employees
-